How to Read SS-31 CoA — Purity Analysis Explained

A Certificate of Analysis for SS-31 (elamipretide) arrives with every legitimate peptide order, but fewer than 30% of researchers actually read past the purity headline. Here's what that costs: batches marked 98% pure can still contain acetate salts, residual solvents, or incorrect molecular weight species that compromise experimental reproducibility. The difference between a CoA you skim and one you actually understand determines whether your mitochondrial function studies produce publishable data or noise.

Our team works directly with research facilities conducting SS-31 trials across metabolic health, cardioprotection, and neurodegenerative models. The pattern is consistent: studies using verified CoA data show reproducible outcomes; those that don't often fail in replication. Reading a CoA correctly isn't about chemistry credentials. It's about knowing which three data points actually matter.

How do you read an SS-31 CoA correctly?

An SS-31 Certificate of Analysis must include HPLC chromatogram data showing purity percentage, mass spectrometry confirming molecular weight (±1 Da of 640.2 g/mol), and residual solvent analysis below ICH Q3C limits. The chromatogram peak area under the main SS-31 signal relative to total area defines true purity. Not the headline percentage alone. Verify the batch number on the vial matches the CoA document before proceeding with any reconstitution or dosing protocol.

Most researchers assume all CoAs follow the same format, but that's incorrect. Third-party testing facilities structure data differently than in-house lab reports, and compounding pharmacies often provide abbreviated certificates that omit critical contamination markers. This article covers how to locate the HPLC purity data, interpret mass spectrometry results, verify batch traceability, and identify red-flag indicators that suggest the peptide shouldn't be used regardless of stated purity.

Step 1: Verify Batch Number and Testing Date Before Reading Data

The batch number printed on the peptide vial must match the batch identifier on the CoA document exactly. Character-for-character, including hyphens and leading zeros. Mismatches indicate you're reading a CoA from a different production run, which means the purity data doesn't apply to the compound in your possession. Testing date matters because peptides degrade over time: an SS-31 batch tested 18 months ago and stored improperly may no longer match the original purity profile, even if the CoA shows 99% at synthesis.

HPLC analysis degrades within 90 days of the test date if storage conditions weren't maintained below −20°C in a desiccated environment. Moisture exposure accelerates peptide bond hydrolysis, which fragments SS-31 into shorter amino acid sequences that retain partial biological activity but produce inconsistent dose-response curves. If the CoA is dated more than six months prior to your order date and the supplier can't provide updated testing, request a new certificate or refuse the batch. Research integrity depends on knowing what you're actually dosing.

Batch traceability also extends to raw material sourcing. Reputable suppliers reference the amino acid synthesis facility or starting material lot numbers in CoA metadata, allowing backward tracing if contamination is discovered post-publication. SS-31 synthesis requires four specific amino acids in exact sequence (D-Arg-Dmt-Lys-Phe-NH₂). Substitution or racemization of any residue creates an analog with altered mitochondrial membrane affinity. The CoA should state whether synthesis used Fmoc solid-phase peptide synthesis (SPPS), which is standard, or liquid-phase methods, which introduce different impurity profiles.

Step 2: Interpret the HPLC Chromatogram for True Purity

The HPLC (High-Performance Liquid Chromatography) chromatogram is the single most important section of any SS-31 CoA. It displays peptide purity as peak area percentage. The area under the primary SS-31 peak divided by total detected peak area across the elution window. A chromatogram showing one dominant peak at 98.3% purity with no secondary peaks above 0.5% indicates high-quality synthesis. Conversely, a 97% headline purity with three secondary peaks at 1.2%, 0.9%, and 0.7% suggests incomplete purification and the presence of deletion sequences or acetylated variants.

Retention time matters as much as peak area. SS-31 elutes at a predictable retention time based on column type and mobile phase composition. Typically between 12–16 minutes on a C18 reverse-phase column with acetonitrile gradients. Peaks appearing earlier than the main signal often represent hydrophilic impurities like residual TFA (trifluoroacetic acid) or salts; peaks eluting later suggest hydrophobic contaminants or aggregated peptide dimers. Neither category is benign: TFA residues above 0.1% by mass can interfere with downstream cellular assays, and peptide dimers alter pharmacokinetics in animal models.

Some suppliers report purity as 'by mass' versus 'by area'. These are not interchangeable. Area purity (standard for HPLC) measures chromatographic signal intensity, which correlates with molar concentration. Mass purity accounts for molecular weight differences between SS-31 and impurities, which can artificially inflate the percentage if heavy-metal contaminants are present. Always confirm which method was used. For SS-31, area purity above 95% is acceptable for most research; anything below 93% introduces too much variability for dose-dependent mitochondrial studies.

Step 3: Confirm Molecular Weight with Mass Spectrometry Data

Mass spectrometry (MS) confirms that the peptide sequence matches SS-31's theoretical molecular weight of 640.2 g/mol (free base form). The CoA should include either ESI-MS (electrospray ionization) or MALDI-TOF (matrix-assisted laser desorption) data showing a primary ion peak at m/z 640.2 ± 1 Da. This tolerance accounts for instrument calibration and isotopic distribution. Deviations beyond ±2 Da indicate synthesis errors, incorrect amino acid incorporation, or post-synthesis modifications like oxidation of the dimethyltyrosine (Dmt) residue.

MS data also reveals acetate or TFA salt content. SS-31 is frequently synthesized as the acetate salt to improve stability, which adds approximately 59 Da per acetate group. A reported molecular weight of 699 g/mol suggests the peptide is supplied as the monoacetate salt. This is acceptable and commonly used in research, but dosing calculations must account for the added mass. If the CoA lists 640.2 g/mol but doesn't specify free base versus salt form, contact the supplier for clarification before calculating molar concentrations for reconstitution.

Fragment ions in the MS spectrum provide additional quality assurance. SS-31 fragmentation under collision-induced dissociation produces predictable b-ions and y-ions corresponding to peptide bond cleavage between specific amino acids. A CoA showing fragment ions at m/z 175 (Dmt immonium ion) and m/z 294 (Lys-Phe dipeptide) confirms the correct sequence. Absence of these fragments or presence of unexpected ions suggests sequence scrambling during synthesis. A red flag that the peptide may not exhibit authentic SS-31 biological activity regardless of stated purity.

SS-31 CoA Data: Element Comparison

Key Takeaways

• The batch number on the peptide vial must match the CoA document exactly. Mismatches mean the purity data does not apply to your compound.
• HPLC purity is measured by peak area percentage. A 98% headline with multiple secondary peaks above 1% is lower quality than 96% with one clean dominant peak.
• SS-31 has a theoretical molecular weight of 640.2 g/mol (free base) or approximately 699 g/mol as the acetate salt. Deviations beyond ±2 Da indicate synthesis errors.
• Residual TFA content above 0.1% by mass interferes with cellular assays and must be disclosed in the CoA solvent analysis section.
• CoAs dated more than six months before your order date may not reflect current peptide stability. Request updated testing or refuse the batch.
• Mass spectrometry fragment ions at m/z 175 and 294 confirm correct SS-31 amino acid sequence. Absence of these fragments suggests sequence scrambling.

What If: SS-31 CoA Scenarios

What If the HPLC Chromatogram Shows Multiple Small Peaks?

Secondary peaks represent impurities. Likely deletion sequences (missing one amino acid), acetylated variants, or oxidized forms of the dimethyltyrosine residue. If any single secondary peak exceeds 1.5% area, the batch purity is functionally lower than the headline percentage. Request the supplier identify the largest impurity peak by MS or reject the batch outright. Multiple small peaks totaling more than 3% aggregate area suggest incomplete HPLC purification post-synthesis.

What If the Molecular Weight Is Off by 16 Da?

A +16 Da shift indicates oxidation of the Dmt (dimethyltyrosine) residue to the corresponding quinone. This modification reduces SS-31's affinity for cardiolipin in the inner mitochondrial membrane, which is the peptide's primary binding target. Oxidized SS-31 retains partial activity but produces inconsistent results across replicates. Do not use batches showing +16 Da shifts. They represent degraded product, not synthesis impurities.

What If the CoA Lists Purity But No HPLC Data?

A CoA stating '98% pure' without an accompanying chromatogram is not verifiable and should be treated as suspect. Reputable suppliers always include raw chromatographic data. The absence suggests either the purity claim is unsupported or the supplier is using a non-standard purity definition (gravimetric purity, which includes salts and moisture). Request full HPLC data or source from a different supplier.

What If Residual TFA Content Isn't Listed?

TFA (trifluoroacetic acid) is used as a cleavage reagent in Fmoc SPPS and is notoriously difficult to remove completely. If the CoA doesn't report TFA content, assume it's present at levels that may interfere with assays involving acidic pH buffers or ion channels. Contact the supplier for residual solvent analysis or run your own ion chromatography if downstream applications are TFA-sensitive.

The Unfiltered Truth About SS-31 CoA Documents

Here's the honest answer: most SS-31 CoAs provided by peptide resellers are recycled documents that don't correspond to the specific batch you received. The industry standard is to provide a 'representative CoA' from a similar production run rather than batch-specific testing, which means the purity data may be directionally accurate but not precise. This practice is legal but scientifically problematic. Batch-to-batch variability in peptide synthesis can produce purity swings of 3–5% even with identical synthesis protocols.

The second uncomfortable reality: purity percentage alone tells you almost nothing about biological activity. A 99% pure SS-31 batch that spent six months at room temperature during shipping and storage may have undergone partial racemization of the D-arginine residue. A modification that doesn't register on standard HPLC but completely abolishes mitochondrial targeting. Without batch-specific storage validation or sterility testing, the CoA is a snapshot of the peptide at synthesis, not at time of use.

If you're conducting work that will be published or submitted for regulatory review, insist on batch-specific CoAs with signed analyst certification and ISO 17025-accredited lab testing. Generic CoAs without analyst signatures or accreditation seals carry no traceability and won't satisfy journal supplementary data requirements. This is non-negotiable for any study involving human-derived cells or animal models.

The final point: learning to read an SS-31 CoA correctly isn't optional if you're working with mitochondrial therapeutics. The difference between a peptide that works and one that doesn't often comes down to contaminants present at sub-1% levels that standard purity reporting ignores. Our experience across mitochondrial function studies consistently shows this: researchers who validate every CoA parameter before starting protocols produce reproducible data; those who rely on headline purity alone encounter unexplained variability that derails entire projects.

If the CoA for your current SS-31 batch shows any of these red flags. Secondary HPLC peaks above 1.5%, molecular weight deviation beyond ±2 Da, missing residual solvent data, or a test date older than six months. Don't proceed with reconstitution. Contact the supplier for clarification or request a replacement batch. The integrity of your mitochondrial research depends on compound identity verification before the first injection, not after inconsistent results force you to backtrack.

You can explore our commitment to verified quality across our Real Peptides catalog, where every batch ships with traceable, batch-specific CoA documentation.